1-9 of 9
Yoji Ishida, M.D.
Close
Sort by
Journal Articles

Recombinant Thrombomodurin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation

Kazuyoshi Ishii, MD, MPH, PhD, Shosaku Nomura, MD, PhD, Tomoki Ito, MD, PhD, Yuta Katayama, MD, PhD, Taiichi Kyo, MD, Shuichi Ota, MD, PhD, Masanori Seki, MD, PhD, Shigeru Chiba, MD, PhD, Yoshinobu Maeda, M.D., Ph.D., Mitsune Tanimoto, MD, PhD, Takayuki Ikezoe, MD. PhD, Hideo Yagi, MD, PhD, Yoji Ishida, M.D., Ph.D., Naohito Fujishima, MD, PhD, Kenichi Sawada, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 5454.
https://doi.org/10.1182/blood.V122.21.5454.5454
Published: 2013
Journal Articles

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Hideo Tanaka, MD, PhD, Jun Imagawa, MD, PhD, Masaya Okada, MD, PhD, Hirohisa Nakamae, MD, PhD, Masayuki Hino, MD, PhD, Kazunori Murai, MD, PhD, Yoji Ishida, M.D., Ph.D., Takashi Kumagai, MD, PhD, Seiichi Sato, MD, Kazuteru Ohashi, MD, PhD, Hisashi Sakamaki, MD, PhD, Hisashi Wakita, MD, PhD, Nobuhiko Uoshima, MD, PhD, Yasunori Nakagawa, MD, Yosuke Minami, MD, PhD, Masahiro Ogasawara, MD, PhD, Tomoharu Takeoka, MD, Hiroshi Akasaka, MD, Satoshi Morita, PhD, Junichi Sakamoto, MD, PhD, Shinya Kimura, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3998.
https://doi.org/10.1182/blood.V122.21.3998.3998
Published: 2013
Journal Articles

The Prospective Analysis Of Clinical Efficacy and Adverse Events In Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Patients With Imatinib Resistance Or Intolerance, Evaluated By European Leukemia Net (ELN) 2013 Criteria

Kazunori Murai, M.D., Ph.D., Tomoaki Akagi, M.D., Ph.D., Kenji Shimosegawa, MD, Kenichi Ishizawa, MD, PhD, Tomohiro Sugawara, MD, Hisayuki Yokoyama, MD, PhD, Hideyoshi Noji, MD, PhD, Kazuei Ogawa, M.D., Ph.D., Katsushi Tajima, MD, PhD, Koji Oba, PhD, Junichi Sakamoto, MD, PhD, Koumei Kubo, MD, PhD, Hisashi Sakamaki, MD, PhD, Hideo Harigae, MD, PhD, Yoji Ishida, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 4027.
https://doi.org/10.1182/blood.V122.21.4027.4027
Published: 2013
Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study Of Dasatinib In Chronic Phase Of Newly Diagnosed Chronic Myeloid Leukemia (CML-CP)

Yoji Ishida, M.D., Ph.D., Kazunori Murai, MD, PhD, Kohei Yamaguchi, M.D., Takuo Miyagishima, MD, PhD, Motohiro Shindo, M.D., Ph.D., Kazuei Ogawa, M.D., Ph.D., Takahiro Nagashima, MD, PhD, Shinji Sato, MD, PhD, Reiko Watanabe, M.D., Ph.D., Satoshi Yamamoto, MD, PhD, Takaaki Hirose, MD, PhD, Yuichi Kato, MD, PhD, Masakatsu Yonezumi, M.D. PhD, Takeshi Kondo, MD., PhD, Nobuo Mochizuki, PhD, Keiko Ohno, PhD, Satoshi Kishino, PhD, Shigeki Ito, M.D., Ph.D., Komei Kubo, MD, PhD, Sohichi Saito, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4031.
https://doi.org/10.1182/blood.V122.21.4031.4031
Published: 2013
Journal Articles

Clinical Efficacy and Safety Of Dasatinib For Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase In Japan

Kohei Yamaguchi, M.D., Kazunori Murai, M.D., Ph.D., Shigeki Ito, M.D., Ph.D., Tomoaki Akagi, M.D., Ph.D., Kazuei Ogawa, M.D., Ph.D., Kuniaki Meguro, M.D., Ph.D., Mitsue Inomata, M.D., Reiko Watanabe, M.D., Ph.D., Takuto Miyagishima, M.D., Kentaro Wakasa, M.D., Motohiro Shindo, M.D., Ph.D., Yasuhiko Tsukushi, M.D., Kohmei Kubo, M.D., Ph.D., Yoji Ishida, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 1493.
https://doi.org/10.1182/blood.V122.21.1493.1493
Published: 2013
Journal Articles

Doripenem Versus Meropenem For Empirical Antimicrobial Therapy In High Risk Febrile Neutropenic Patients With Hematological Malignancies: A Randomized, Controlled Trial

Yuka Fujisawa, M.D., Tatsuo Oyake, M.D., Ph.D., Takahiro Mine, M.D., Yusei Aoki, M.D., Yasuhiko Tsukushi, M.D., Ph.D., Takeshi Sugawara, M.D., Masato Seguchi, M.D., Ph.D., Ichiro Hanamura, M.D., Ph.D., Yasuaki Nakagawa, M.D., Ph.D., Kazunori Murai, M.D., Ph.D., Shigeki Ito, M.D., Ph.D., Yoji Ishida, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 4716.
https://doi.org/10.1182/blood.V122.21.4716.4716
Published: 2013
Journal Articles

YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells

Shigeki Ito, M.D., Ph.D., Maki Asahi, MD, Ryousei Sasaki, MD, Tatsuo Oyake, M.D., Ph.D., Hideto Tamura, MD, PhD, Yoji Ishida, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 1667.
https://doi.org/10.1182/blood.V122.21.1667.1667
Published: 2013
Journal Articles

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Yukiteru Fujishima, MD, Yasuhiko Tsukushi, M.D., Takahiro Mine, MD., Tatsuo Oyake, M.D., Ph.D., Shigeki Ito, M.D., Ph.D., Yoji Ishida, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 1071.
https://doi.org/10.1182/blood.V122.21.1071.1071
Published: 2013
Journal Articles

Thrombocytopoiesis Is Not Regulated by Thrombopoietin (TPO) but Proplatelet Formation (PPF) Stimulating Factor.

Kazunori Murai, MD, Shugo Kowata, M.D., Yasuhiko Tsukushi, M.D., Mamiko Ishiguro, M.D., Tatsuo Oyake, M.D., Takeshi Sugawara, M.D., Yoji Ishida, M.D.
Journal: Blood
Blood (2006) 108 (11): 1112.
https://doi.org/10.1182/blood.V108.11.1112.1112
Published: 2006